Can I just say what you hit on is exactly it, because we do clinical trials internationally. We know that with rare diseases we're not going to get all of the information from patients that are just going to be in one locale.
Post-market is the same thing. Why won't we assume that we can go to one locale, one province, one hospital, or one country even? We need to be collaborating internationally.
The challenge is that the access criteria are not the same internationally. Unless Canada is willing and able to collaborate.... Mind you we can adjust some of it scientifically, etc., but we need to be thinking about these as ongoing international environments in order to develop the monitoring. It means, in many respects, that collaboration must go from the beginning all the way through to the end.